These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 38714472

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR, SECURE study group.
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
    Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, Fishman S, Levchenko O, Cheon JH, Scribano ML, Mateescu RB, Lee KM, Eun CS, Lee SJ, Lee SY, Kim H, Schreiber S, Fowler H, Cheung R, Kim YH.
    Lancet; 2019 Apr 27; 393(10182):1699-1707. PubMed ID: 30929895
    [Abstract] [Full Text] [Related]

  • 4. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K, Rutka M, Ferenci T, Nagy F, Bálint A, Bor R, Milassin Á, Fábián A, Szántó K, Végh Z, Kürti Z, Lakatos PL, Szepes Z, Molnár T.
    Expert Opin Biol Ther; 2017 Nov 27; 17(11):1325-1332. PubMed ID: 28819991
    [Abstract] [Full Text] [Related]

  • 5. Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.
    Park J, Cheon JH, Lee KM, Kim YH, Ye BD, Eun CS, Kim SH, Lee SH, Lee JH, Schreiber S.
    Gut Liver; 2023 May 15; 17(3):430-440. PubMed ID: 35975641
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.
    Bronswijk M, Moens A, Lenfant M, Tops S, Compernolle G, Van Assche G, Vermeire S, Gils A, Ferrante M.
    Inflamm Bowel Dis; 2020 Mar 04; 26(4):628-634. PubMed ID: 31400283
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
    Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J.
    Scand J Gastroenterol; 2016 Sep 04; 51(9):1062-8. PubMed ID: 27002981
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
    Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, Kang HW, Kim JW.
    J Gastroenterol Hepatol; 2015 Dec 04; 30(12):1705-12. PubMed ID: 25974251
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Ratnakumaran R, To N, Gracie DJ, Selinger CP, O'Connor A, Clark T, Carey N, Leigh K, Bourner L, Ford AC, Hamlin PJ.
    Scand J Gastroenterol; 2018 Jun 04; 53(6):700-707. PubMed ID: 29687730
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
    Farkas K, Rutka M, Golovics PA, Végh Z, Lovász BD, Nyári T, Gecse KB, Kolar M, Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Malickova K, Bálint A, Nagy F, Bor R, Milassin Á, Szepes Z, Palatka K, Lakatos PL, Lukas M, Molnár T.
    J Crohns Colitis; 2016 Nov 04; 10(11):1273-1278. PubMed ID: 27106537
    [Abstract] [Full Text] [Related]

  • 17. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro Benallal D, Benítez Roldán A, Merino V, Ramirez G, Calleja-Hernández MA, Caunedo Álvarez A, Romero Gómez M.
    Eur J Gastroenterol Hepatol; 2017 Nov 04; 29(11):1290-1295. PubMed ID: 28902041
    [Abstract] [Full Text] [Related]

  • 18. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.
    Ther Drug Monit; 2019 Jun 04; 41(3):317-324. PubMed ID: 30633088
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.